https://www.fda.gov/drugs/drug-approvals-and-databases/drug-trials-snapshots-komzifti
KOMZIFTI is a cancer drug that is used to treat adult patients with acute myeloid leukemia (AML) with a susceptible nucleophosmin 1 (NPM1) mutation that has come back or has not improved after previous treatment(s) and who have no satisfactory alternative treatment options.
No hay comentarios:
Publicar un comentario